{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:11Z","timestamp":1778780111852,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00280-011-1753-2","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T19:40:36Z","timestamp":1319744436000},"page":"773-780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"69","author":[{"given":"Iacopo","family":"Petrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Lencioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Ricasoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Iannopollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Orlandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Oliveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Bartolozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,28]]},"reference":[{"key":"1753_CR1","unstructured":"(1967) Malignant hepatoma-controlled therapeutic trials. South African primary liver cancer research group. Initial report. S Afr Med J 41:309\u2013314"},{"key":"1753_CR2","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, Mori A, Le Berre M, Voliotis D, Saltz L (2008) Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S\u00a0+\u00a0D) versus placebo plus doxorubicin (P\u00a0+\u00a0D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). Gastrointestinal cancers symposium meeting abstract, 128","DOI":"10.1016\/S1359-6349(07)71003-0"},{"key":"1753_CR3","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293\u20134300","journal-title":"J Clin Oncol"},{"key":"1753_CR4","unstructured":"Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembe BA, Piccart-Ghebart M, Hendlisz A Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 Trial. J Clin Pharmacol"},{"key":"1753_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","volume":"59","author":"YS Chang","year":"2007","unstructured":"Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S (2007) Sorafenib (BAY 43\u20139006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561\u2013574","journal-title":"Cancer Chemother Pharmacol"},{"key":"1753_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334","journal-title":"Lancet Oncol"},{"key":"1753_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/1097-0142(197401)33:1<193::AID-CNCR2820330128>3.0.CO;2-S","volume":"33","author":"HL Davis Jr","year":"1974","unstructured":"Davis HL Jr, Ramirez G, Ansfield FJ (1974) Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 33:193\u2013197","journal-title":"Cancer"},{"key":"1753_CR8","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1002\/1097-0142(197811)42:5<2149::AID-CNCR2820420510>3.0.CO;2-5","volume":"42","author":"G Falkson","year":"1978","unstructured":"Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP (1978) Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42:2149\u20132156","journal-title":"Cancer"},{"key":"1753_CR9","doi-asserted-by":"crossref","first-page":"iii87","DOI":"10.1093\/annonc\/mdh909","volume":"15","author":"A Figer","year":"2004","unstructured":"Figer A, Moscovici M, Bulocinic S, Radu P, Astmon J, Shmuely E, Laba O, Gadish D, Brendel E, Schwartz B (2004) Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors. Ann Oncol 15:iii87\u2013iii88","journal-title":"Ann Oncol"},{"key":"1753_CR10","doi-asserted-by":"crossref","first-page":"iii87","DOI":"10.1093\/annonc\/mdh909","volume":"15","author":"AMM Figer","year":"2004","unstructured":"Figer AMM, Bulocinic S, Radu P, Astmon J, Shmuely E, Laba O, Gadish D, Brendel E, Schwartz B (2004) Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors. Ann Oncol 15: iii87\u201388","journal-title":"Ann Oncol"},{"key":"1753_CR11","volume-title":"Global cancer facts & figures\u00a02007","author":"MJA Garcia","year":"2007","unstructured":"Garcia MJA, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global cancer facts & figures\u00a02007. American Cancer Society, Atlanta"},{"key":"1753_CR12","doi-asserted-by":"crossref","first-page":"e14522","DOI":"10.1200\/jco.2010.28.15_suppl.e14522","volume":"28","author":"CH Hsu","year":"2010","unstructured":"Hsu CH, Wong CCY, Yao T, Tang V, Chan P, Chiu J, Fan S, Poon R (2010) Efficacy and tolerability of sorafenib in elderly patients with advanced hepatocellular carcinoma. J Clin Oncol 28:e14522 abstr","journal-title":"J Clin Oncol"},{"key":"1753_CR13","doi-asserted-by":"crossref","unstructured":"Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL Phase II study of combining sorafenib with metronomic tegafur\/uracil for advanced hepatocellular carcinoma. J Hepatol 53:126\u2013131","DOI":"10.1016\/j.jhep.2010.01.035"},{"key":"1753_CR14","unstructured":"Infante JR, Jones SF, Bendell JC, Greco FA, Yardley DA, Lane CM, Spigel DR, Hainsworth JD, Burris III HA A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Cancer Chemother Pharmacol"},{"key":"1753_CR15","unstructured":"Joensuu H, De Braud F, Grigagni G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, Casali PG Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer"},{"key":"1753_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1055-3207(02)00075-3","volume":"12","author":"PJ Johnson","year":"2003","unstructured":"Johnson PJ (2003) Are there indications for chemotherapy in hepatocellular carcinoma? Surg Oncol Clin N Am 12:127\u2013134","journal-title":"Surg Oncol Clin N Am"},{"key":"1753_CR17","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1002\/ijc.22616","volume":"120","author":"KM Kee","year":"2007","unstructured":"Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN (2007) Validation of clinical AJCC\/UICC TNM staging system for hepatocellular carcinoma: analysis of 5, 613 cases from a medical center in southern Taiwan. Int J Cancer 120:2650\u20132655","journal-title":"Int J Cancer"},{"key":"1753_CR18","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/1097-0142(197705)39:5<1930::AID-CNCR2820390503>3.0.CO;2-7","volume":"39","author":"PS Kennedy","year":"1977","unstructured":"Kennedy PS, Lehane DE, Smith FE, Lane M (1977) Oral fluorouracil therapy of hepatoma. Cancer 39:1930\u20131935","journal-title":"Cancer"},{"key":"1753_CR19","unstructured":"Lee SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Yim DS, Lim HY Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest New Drugs"},{"key":"1753_CR20","doi-asserted-by":"crossref","unstructured":"Lencioni R, Llovet JM Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360","DOI":"10.1055\/s-0030-1247132"},{"key":"1753_CR21","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/1097-0142(197705)39:5<1936::AID-CNCR2820390504>3.0.CO;2-N","volume":"39","author":"JS Link","year":"1977","unstructured":"Link JS, Bateman JR, Paroly WS, Durkin WJ, Peters RL (1977) 5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases. Cancer 39:1936\u20131939","journal-title":"Cancer"},{"key":"1753_CR22","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res 66:11851\u201311858","journal-title":"Cancer Res"},{"key":"1753_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00535-005-1566-3","volume":"40","author":"JM Llovet","year":"2005","unstructured":"Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40:225\u2013235","journal-title":"J Gastroenterol"},{"key":"1753_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698\u2013711","journal-title":"J Natl Cancer Inst"},{"key":"1753_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"1753_CR26","doi-asserted-by":"crossref","unstructured":"Luporini G, Labianca R, Pancera G (1993) Medical treatment of hepatocellular carcinoma. J Surg Oncol (Suppl 3):115-118","DOI":"10.1002\/jso.2930530531"},{"key":"1753_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529\u2013538","journal-title":"J Hepatol"},{"key":"1753_CR28","doi-asserted-by":"crossref","unstructured":"Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D\u2019Agostino A, Faiola V, Addeo R Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 66:837\u2013844","DOI":"10.1007\/s00280-009-1226-z"},{"key":"1753_CR29","unstructured":"Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, Kakeji Y, Onozawa Y, Yamasaki M, Ohtsu A Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer"},{"key":"1753_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1753_CR31","doi-asserted-by":"crossref","unstructured":"Ueshima K, Kudo M, Tanaka M, Kumada T, Sakurai T, Chung H, Hagiwara S, Minami Y, Inoue T, Yada N, Kitai S, Takita M, Hayaishi S (2011) Phase I study of sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy. J Clin Oncol (Suppl 29)","DOI":"10.1200\/jco.2011.29.15_suppl.e14563"},{"key":"1753_CR32","doi-asserted-by":"crossref","unstructured":"Villanueva A, Minguez B, Forner A, Reig M, Llovet JM Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61:317\u2013328","DOI":"10.1146\/annurev.med.080608.100623"},{"key":"1753_CR33","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2174\/1381612023393026","volume":"8","author":"S Wilhelm","year":"2002","unstructured":"Wilhelm S, Chien DS (2002) BAY 43\u20139006: preclinical data. Curr Pharm Des 8:2255\u20132257","journal-title":"Curr Pharm Des"},{"key":"1753_CR34","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109","journal-title":"Cancer Res"},{"key":"1753_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S1359-6349(09)72082-8","volume":"7","author":"T Yau","year":"2009","unstructured":"Yau T, Chan P, Cheung FY, Lee AS, Yau TK, Choo SP, Lau J, Wong JS, Fan ST, Poon RT (2009) Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer Suppl 7:20\u201321","journal-title":"Eur J Cancer Suppl"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1753-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-011-1753-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1753-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1753-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:41:06Z","timestamp":1659058866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-011-1753-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,28]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1753-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,28]]},"assertion":[{"value":"16 August 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}